GlassScriptPhysician profile
Meg W Ellis
NPI 1083910384
$8,406.95
in general payments reported to CMS, 2019-2025
51 companies · $764 in 2025
The $764 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,192 · 2022: $2,128 · 2023: $2,139 · 2024: $1,184 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,086.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,428.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,397.02 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $992.42 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $578.30 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $429.41 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $415.66 | 2022-2025 | Auvelity, Symbravo |
| Dexcom, INC. | $267.78 | 2021-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $256.60 | 2021-2024 | Rexulti |
| Esperion Therapeutics, INC. | $252.10 | 2021-2022 | |
| Bausch Health US, LLC | $204.00 | 2021-2023 | Aplenzin |
| Novartis Pharmaceuticals Corporation | $191.60 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.66 | 2021-2024 | Xifaxan |
| Amgen INC. | $148.30 | 2021-2023 | Repatha, Otezla |
| Shield Therapeutics INC | $141.58 | 2023-2025 | Accrufer |
| Antares Pharma, INC. | $130.46 | 2021-2023 | Tlando, Xyosted, Nocdurna |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $124.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $98.02 | 2023-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.34 | 2021-2022 | |
| Corcept Therapeutics | $81.92 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $71.04 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $70.52 | 2022 | |
| Clarus Therapeutics INC. | $67.16 | 2021 | |
| Phathom Pharmaceuticals, INC. | $66.45 | 2025 | Voquezna |
| Arbor Pharmaceuticals, INC. | $64.74 | 2021-2022 | |
| Amarin Pharma, INC. | $50.92 | 2021 | |
| Ibsa Pharma INC. | $44.69 | 2022-2025 | Flector, Licart, Tirosint |
| Halozyme INC | $43.76 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $43.75 | 2021 | |
| Xeris Pharmaceuticals, INC. | $38.37 | 2023 | Gvoke Hypopen |
| Almatica Pharma LLC | $33.91 | 2021-2022 | |
| Lundbeck LLC | $32.85 | 2022 | |
| Mylan Specialty L.P. | $28.05 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.99 | 2025 | Caplyta |
| Inogen, INC. | $25.79 | 2023 | Inogen At Home Stationary Concentrator |
| Impel Pharmaceuticals INC. | $24.31 | 2022 | |
| Inspire Medical Systems, INC. | $24.00 | 2025 | Inspire |
| Vanda Pharmaceuticals INC. | $23.72 | 2025 | Hetlioz, Fanapt |
| Genzyme Corporation | $18.48 | 2021 | |
| Tris Pharma INC | $17.58 | 2023 | Dyanavel Xr |
| Azurity Pharmaceuticals, INC. | $17.18 | 2023 | Horizant |
| Pfizer INC. | $17.07 | 2023 | |
| Intra-Sana Laboratories | $16.89 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Medtronic, INC. | $14.98 | 2024 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $14.66 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.27 | 2023 | Xarelto |
| Tolmar, INC. | $13.93 | 2024 | |
| Hikma Pharmaceuticals USA | $13.71 | 2023 | Ryaltris, Mitigare |
| Sanofi-Aventis U.S. LLC | $12.02 | 2021 | |
| Nevro Corp. | $11.88 | 2021 | |
| Glaxosmithkline, LLC. | $11.73 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meg Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.